IMW 2019 | Multiple myeloma MRD assessment

Fengyan Jin

Prof Fengyan Jin of Jilin University, Jilin, China, outlines the issues with current criteria regarding (measurable residual disease) MRD testing within clinical trials, namely the depth of MRD sensitivity, which cannot always be reached, and the suggested duration of MRD. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  
Similar topics